Naslov
Accelerating the development and validation of liquid biopsy for early cancer screening and treatment tailoring

Autori
Horgan, Denis ; Čufer, Tanja ; Gatto, Francesco ; Lugowska, Iwona ; Verbanac, Donatella ; Carvalho, Ângela ; Lal, Jonathan A. ; Kozaric, Marta ; Toomey, Sinead ; Ivanov, Hristo Y. ; Longshore, John ; Malapelle, Umberto ; Hasenleithner, Samantha ; Hofman, Paul ; Alix-Panabières, Catherine

Izvornik
Healthcare (2227-9032) 10 (2022), 9; 1-21

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
cancer ; diagnosis ; governance ; healthcare ; implementation ; legislation ; liquid biopsy ; personalized medicine ; policy framework ; technology ; treatment

Sažetak
Liquid biopsy (LB) is a minimally invasive method which aims to detect circulating tumor-derived components in body fluids. It provides an alternative to current cancer screening methods that use tissue biopsies for the confirmation of diagnosis. This paper attempts to determine how far the regulatory, policy, and governance framework provide support to LB implementation into healthcare systems and how the situation can be improved. For that reason, the European Alliance for Personalised Medicine (EAPM) organized series of expert panels including different key stakeholders to identify different steps, challenges, and opportunities that need to be taken to effectively implement LB technology at the country level across Europe. To accomplish a change of patient care with an LB approach, it is required to establish collaboration between multiple stakeholders, including payers, policymakers, the medical and scientific community, and patient organizations, both at the national and international level. Regulators, pharma companies, and payers could have a major impact in their own domain. Linking national efforts to EU efforts and vice versa could help in implementation of LB across Europe, while patients, scientists, physicians, and kit manufacturers can generate a pull by undertaking more research into biomarkers.

Izvorni jezik
Engleski

Znanstvena područja
Interdisciplinarne prirodne znanosti, Temeljne medicinske znanosti, Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita, Farmacija

POVEZANOST RADA